Health Canada Has Approved Oral Plaque Psoriasis Treatment

 Health Canada Has Approved Oral Plaque Psoriasis Treatment

Bristol Myers Squibb Canada (BMS) announced that Health Canada has approved SOTYKTU (deucravacitinib tablets), an oral tablet for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Psoriasis is a chronic inflammatory condition impacting the lives of nearly a million Canadians across the country. The severity of the condition ranges from dandruff-like scales to patches that cover large areas of skin. Plaque psoriasis is the most common type of psoriasis, most often appearing on elbows and knees, and with over half of patients on their scalps. These patches of affected skin are inflamed and sensitive to the touch, resulting in experiences that impact daily activities such as walking, exercising, going to restaurants or shopping for groceries. Additionally, psoriasis patients often face mental health challenges resulting in issues such as social anxiety, depression and lack of self-esteem.

SOTYKTU is a tyrosine kinase 2 (TYK2) inhibitor, which works by selectively blocking the activity of the "TYK2" enzyme, which is involved in the process of inflammation. Studies have demonstrated that TYK2 inhibitors are well tolerated in patients with psoriasis.


Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers from Tablets & Capsules – all delivered right to your inbox! Sign up now!
 

Related Product Categories